Cargando…
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease
BACKGROUND: Mitochondrial dysfunction, oxidative stress and their interplay are core pathological features of Parkinson’s disease. In dopaminergic neurons, monoamines and their metabolites provide an additional source of reactive free radicals during their breakdown by monoamine oxidase or auto-oxid...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711075/ https://www.ncbi.nlm.nih.gov/pubmed/26758813 http://dx.doi.org/10.1186/s13024-015-0067-y |
_version_ | 1782409913926942720 |
---|---|
author | Baranyi, Mária Porceddu, Pier Francesca Gölöncsér, Flóra Kulcsár, Szabina Otrokocsi, Lilla Kittel, Ágnes Pinna, Annalisa Frau, Lucia Huleatt, Paul B. Khoo, Mui-Ling Chai, Christina L. L. Dunkel, Petra Mátyus, Peter Morelli, Micaela Sperlágh, Beáta |
author_facet | Baranyi, Mária Porceddu, Pier Francesca Gölöncsér, Flóra Kulcsár, Szabina Otrokocsi, Lilla Kittel, Ágnes Pinna, Annalisa Frau, Lucia Huleatt, Paul B. Khoo, Mui-Ling Chai, Christina L. L. Dunkel, Petra Mátyus, Peter Morelli, Micaela Sperlágh, Beáta |
author_sort | Baranyi, Mária |
collection | PubMed |
description | BACKGROUND: Mitochondrial dysfunction, oxidative stress and their interplay are core pathological features of Parkinson’s disease. In dopaminergic neurons, monoamines and their metabolites provide an additional source of reactive free radicals during their breakdown by monoamine oxidase or auto-oxidation. Moreover, mitochondrial dysfunction and oxidative stress have a supraadditive impact on the pathological, cytoplasmic accumulation of dopamine and its subsequent release. Here we report the effects of a novel series of potent and selective MAO-B inhibitory (hetero)arylalkenylpropargylamine compounds having protective properties against the supraadditive effect of mitochondrial dysfunction and oxidative stress. RESULTS: The (hetero)arylalkenylpropargylamines were tested in vitro, on acute rat striatal slices, pretreated with the complex I inhibitor rotenone and in vivo, using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced acute, subchronic, and chronic experimental models of Parkinson’s disease in mice. The compounds exhibited consistent protective effects against i) in vitro oxidative stress induced pathological dopamine release and the formation of toxic dopamine quinone in the rat striatum and rescued tyrosine hydroxylase positive neurons in the substantia nigra after rotenone treatment; ii) in vivo MPTP-induced striatal dopamine depletion and motor dysfunction in mice using acute and subchronic, delayed application protocols. One compound (SZV558) was also examined and proved to be protective in a chronic mouse model of MPTP plus probenecid (MPTPp) administration, which induces a progressive loss of nigrostriatal dopaminergic neurons. CONCLUSIONS: Simultaneous inhibition of MAO-B and oxidative stress induced pathological dopamine release by the novel propargylamines is protective in animal models and seems a plausible strategy to combat Parkinson’s disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13024-015-0067-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4711075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47110752016-01-14 Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease Baranyi, Mária Porceddu, Pier Francesca Gölöncsér, Flóra Kulcsár, Szabina Otrokocsi, Lilla Kittel, Ágnes Pinna, Annalisa Frau, Lucia Huleatt, Paul B. Khoo, Mui-Ling Chai, Christina L. L. Dunkel, Petra Mátyus, Peter Morelli, Micaela Sperlágh, Beáta Mol Neurodegener Research Article BACKGROUND: Mitochondrial dysfunction, oxidative stress and their interplay are core pathological features of Parkinson’s disease. In dopaminergic neurons, monoamines and their metabolites provide an additional source of reactive free radicals during their breakdown by monoamine oxidase or auto-oxidation. Moreover, mitochondrial dysfunction and oxidative stress have a supraadditive impact on the pathological, cytoplasmic accumulation of dopamine and its subsequent release. Here we report the effects of a novel series of potent and selective MAO-B inhibitory (hetero)arylalkenylpropargylamine compounds having protective properties against the supraadditive effect of mitochondrial dysfunction and oxidative stress. RESULTS: The (hetero)arylalkenylpropargylamines were tested in vitro, on acute rat striatal slices, pretreated with the complex I inhibitor rotenone and in vivo, using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced acute, subchronic, and chronic experimental models of Parkinson’s disease in mice. The compounds exhibited consistent protective effects against i) in vitro oxidative stress induced pathological dopamine release and the formation of toxic dopamine quinone in the rat striatum and rescued tyrosine hydroxylase positive neurons in the substantia nigra after rotenone treatment; ii) in vivo MPTP-induced striatal dopamine depletion and motor dysfunction in mice using acute and subchronic, delayed application protocols. One compound (SZV558) was also examined and proved to be protective in a chronic mouse model of MPTP plus probenecid (MPTPp) administration, which induces a progressive loss of nigrostriatal dopaminergic neurons. CONCLUSIONS: Simultaneous inhibition of MAO-B and oxidative stress induced pathological dopamine release by the novel propargylamines is protective in animal models and seems a plausible strategy to combat Parkinson’s disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13024-015-0067-y) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-13 /pmc/articles/PMC4711075/ /pubmed/26758813 http://dx.doi.org/10.1186/s13024-015-0067-y Text en © Baranyi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Baranyi, Mária Porceddu, Pier Francesca Gölöncsér, Flóra Kulcsár, Szabina Otrokocsi, Lilla Kittel, Ágnes Pinna, Annalisa Frau, Lucia Huleatt, Paul B. Khoo, Mui-Ling Chai, Christina L. L. Dunkel, Petra Mátyus, Peter Morelli, Micaela Sperlágh, Beáta Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease |
title | Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease |
title_full | Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease |
title_fullStr | Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease |
title_full_unstemmed | Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease |
title_short | Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease |
title_sort | novel (hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of parkinson’s disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711075/ https://www.ncbi.nlm.nih.gov/pubmed/26758813 http://dx.doi.org/10.1186/s13024-015-0067-y |
work_keys_str_mv | AT baranyimaria novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT porceddupierfrancesca novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT goloncserflora novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT kulcsarszabina novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT otrokocsililla novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT kittelagnes novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT pinnaannalisa novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT fraulucia novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT huleattpaulb novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT khoomuiling novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT chaichristinall novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT dunkelpetra novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT matyuspeter novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT morellimicaela novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease AT sperlaghbeata novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease |